CpG ODN, a TLR9 agonist, has been widely used as an adjuvant in cancer vaccines, because of its ability to enhance the capacity of Th1-type CD4+ T cell responses and antigen-specific CD8+ T CTL responses. Here, CD8A is linked to cancer.